Back to search

Article

Safety and Immunogenicity of a VLP Poliovirus Vaccine: A Phase 1 Trial

2026-08-17

Abstract excerpt

<h4>ABSTRACT</h4> <h4>BACKGROUND</h4> Current polio vaccines face challenges including vaccine-derived poliovirus and high-containment manufacturing. We evaluated a recombinant trivalent virus-like particle (VLP)-based poliovirus vaccine (VPV) for safety and immunogenicity in a first-in-human phase 1 trial. <h4>METHODS</h4> In this randomized, observer-blind, active-controlled trial, 72 healthy adults (18 to 54...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9929e2a9-5ef6-5c8d-8ae2-388755c4cd5e
DOI
10.64898/2026.08.14.26360426
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Safety and Immunogenicity of a VLP Poliovirus Vaccine: A Phase 1 TrialDOI 10.64898/2026.08.14.26360426
First-in-human, phase 1, randomized, observer-blind, controlled trial to assess the safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adultsSemantic proximity
Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial.Semantic proximity
Risk-free polio vaccine: Recombinant expression systems for production of stabilised virus-like particlesSemantic proximity
Platforms, advances, and technical challenges in virus-like particles-based vaccinesSemantic proximity
Recombinant expression systems for production of stabilised virus-like particles as next-generation polio vaccinesSemantic proximity
First-in-Human Trial of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine with Adjuvant of Aluminum Hydroxide and CpG 1018Semantic proximity
Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical developmentSemantic proximity
[Poliomyelitis vaccine].Semantic proximity
Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trialSemantic proximity
The efficacy, safety and immunogenicity Nanocovax: results of a randomized, double-blind, placebo-controlled Phase 3 trialSemantic proximity
Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in PlantsSemantic proximity
Virus-like particle-based human vaccines: quality assessment based on structural and functional propertiesSemantic proximity
Select a neighboring publication to make it the new centre.